Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H1 2016

Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H1 2016
Published Jun 30, 2016
78 pages — Published Jun 30, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H1 2016, provides in depth analysis on Smoothened Homolog (Protein Gx or SMO) targeted pipeline therapeutics.

The report provides comprehensive information on the Smoothened Homolog (Protein Gx or SMO), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Smoothened Homolog (Protein Gx or SMO) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Smoothened Homolog (Protein Gx or SMO)
- The report reviews Smoothened Homolog (Protein Gx or SMO) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Smoothened Homolog (Protein Gx or SMO) targeted therapeutics and enlists all their major and minor projects
- The report assesses Smoothened Homolog (Protein Gx or SMO) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Smoothened Homolog (Protein Gx or SMO) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Smoothened Homolog (Protein Gx or SMO)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by un

  
Source:
Document ID
GMDHC0263TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables51
  List of Figures51
Introduction61
  Global Markets Direct Report Coverage61
Smoothened Homolog (Protein Gx or SMO) Overview71
Therapeutics Development84
  Smoothened Homolog (Protein Gx or SMO) Products under Development by Stage of Development81
  Smoothened Homolog (Protein Gx or SMO) Products under Development by Therapy Area91
  Smoothened Homolog (Protein Gx or SMO) Products under Development by Indication102
Smoothened Homolog (Protein Gx or SMO) Pipeline Products Glance122
  Late Stage Products121
  Early Stage Products131
Smoothened Homolog (Protein Gx or SMO) Products under Development by Companies143
Smoothened Homolog (Protein Gx or SMO) Products under Development by Universities/Institutes172
Smoothened Homolog (Protein Gx or SMO) Therapeutics Assessment196
  Assessment by Monotherapy/Combination Products191
  Assessment by Mechanism of Action201
  Assessment by Route of Administration212
  Assessment by Molecule Type232
Smoothened Homolog (Protein Gx or SMO) Companies Involved in Therapeutics Development259
  BeiGene, Ltd.251
  F. Hoffmann-La Roche Ltd.261
  Ignyta, Inc.271
  Mayne Pharma Group Limited281
  Novartis AG291
  PellePharm, Inc.301
  Pfizer Inc.311
  Redx Pharma Plc321
  Stemline Therapeutics, Inc.331
Smoothened Homolog (Protein Gx or SMO) Drug Profiles3425
  glasdegib Drug Profile342
  GSA-10 Drug Profile361
  itraconazole Drug Profile373
  LEQ-506 Drug Profile401
  Monoclonal Antibody to Inhibit Smoothened for Oncology Drug Profile411
  patidegib hydrochloride Drug Profile421
  RDX-001 Drug Profile431
  Small Molecules to Antagonize Smoothened (Smo) Receptor for Cancer Drug Profile441
  Small Molecules to Inhibit Smoothened Homolog for Oncology Drug Profile451
  sonidegib phosphate Drug Profile465
  taladegib Drug Profile512
  vismodegib Drug Profile536
Smoothened Homolog (Protein Gx or SMO) Dormant Projects594
Smoothened Homolog (Protein Gx or SMO) Discontinued Products631
Smoothened Homolog (Protein Gx or SMO) Featured News &Press Releases6413
  Jun 02, 2016: Curis Announces Presentations Related to Erivedge at 2016 ASCO Annual Meeting641
  Jun 02, 2016: FDA Grants Orphan Drug Designation to SUBA-Itraconazole for Treatment of Patients with BCCNS641
  Sep 29, 2015: HedgePath Pharmaceuticals Announces Commencement of Patient Treatment in its Phase II(b) Clinical Trial651
  Aug 21, 2015: HedgePath Pharmaceuticals Launches Clinical Trial for its Proposed Cancer Treatment651
  Aug 20, 2015: Novartis drug Odomzo gains EU approval for locally advanced basal cell carcinoma, providing new non-invasive therapy for patients662
  Jul 24, 2015: FDA approves Novartis drug Odomzo (sonidegib) for locally advanced basal cell carcinoma (laBCC), a form of skin cancer681
  May 20, 2015: Curis Announces Presentations of Erivedge Clinical Data at 2015 ASCO Annual Meeting681
  May 18, 2015: New Equity Investment In Hedgepath Pharmaceuticals Ahead Of Commencing Phase IIB Trial With Suba-Itraconazole In Skin Cancer691
  Mar 09, 2015: Skin tumors develop specific mutations to resist drug, researchers say702
  Mar 02, 2015: Basal Cell Carcinoma Drug Encourages Both Cancer Regression and Loss of Taste in Patients721
  Dec 16, 2014: HedgePath Pharmaceuticals Receives IND Clearance to Commence Development of its Proposed Cancer Treatment731
  Nov 18, 2014: HedgePath Pharmaceuticals Files IND Application731
  Sep 17, 2014: Novartis presents oncology research advances with new data on sonidegib at ESMO 2014741
  Jun 23, 2014: Curis Announces Investigational New Drug Application Filing by Roche to Initiate a Phase II Study of Erivedge (vismodegib) in Idiopathic Pulmonary Fibrosis751
  Jun 01, 2014: Pivotal data for Novartis' investigational compound LDE225 show marked tumor responses in advanced basal cell carcinoma752
Appendix772
  Methodology771
  Coverage771
  Secondary Research771
  Primary Research771
  Expert Panel Validation771
  Contact Us771
  Disclaimer781

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H1 2016" Jun 30, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Smoothened-Homolog-Protein-Gx-or-SMO-Pipeline-Review-H1-2016-2088-16130>
  
APA:
Global Markets Direct - Market Research. (2016). Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H1 2016 Jun 30, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Smoothened-Homolog-Protein-Gx-or-SMO-Pipeline-Review-H1-2016-2088-16130>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.